Skip to main content
Ozempic

Ozempic for Chronic Kidney Disease: How Semaglutide Can Benefit Kidney Function

Alyssa Billingsley, PharmDSophie Vergnaud, MD
Written by Alyssa Billingsley, PharmD | Reviewed by Sophie Vergnaud, MD
Updated on March 13, 2026

Key takeaways:

  • Ozempic (semaglutide) is now FDA approved for heart and kidney protection for adults with Type 2 diabetes and chronic kidney disease (CKD).

  • In a major clinical trial, Ozempic lowered the risk of serious kidney-related events by 24%. It also lowered the risk of major cardiovascular events and death from any cause.

  • Ozempic is only approved for people with both Type 2 diabetes and CKD, though researchers are studying potential benefits in other groups.

Chronic kidney disease (CKD) is a serious complication of Type 2 diabetes, affecting up to 40% of people with the condition. Over time, high blood glucose (blood sugar) levels can damage blood vessels in the kidneys, leading to a gradual decline in kidney function.

In January 2025, the FDA approved Ozempic (semaglutide) for kidney protection benefits in people with Type 2 diabetes and CKD. Semaglutide — already known for its weight-loss and heart-health benefits — is the first in its class to receive approval for both cardiovascular and kidney protection in this high-risk population.

This latest approval adds to the growing list of reasons why healthcare professionals may recommend Ozempic for Type 2 diabetes over other options. But who stands to gain the most from this medication? Here’s what you need to know about Ozempic for chronic kidney disease.

What is Ozempic?

Ozempic is a once-weekly injection that belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist class. It was originally approved to help manage blood sugar levels in adults with Type 2 diabetes. The active ingredient, semaglutide, is also available in a higher-dose version called Wegovy, which is approved for weight loss.

Later, the FDA expanded Ozempic’s approval to include lowering the risk of serious cardiovascular problems (like heart attack, stroke, or cardiovascular death) in people with Type 2 diabetes and heart disease.

But in addition to its heart-health benefits, growing research has also shown Ozempic’s potential for kidney protection. This latest FDA approval confirms Ozempic’s role in providing kidney benefits.

Can Ozempic help with chronic kidney disease?

Yes, studies have shown that Ozempic can protect the kidneys in people with CKD and Type 2 diabetes. And there’s some evidence that semaglutide’s kidney benefits may extend to certain people without diabetes, too.

Results from the FLOW clinical trial were used to support Ozempic’s approval for kidney-related benefits. The trial found that Ozempic lowered the risk of major kidney disease-related events by 24%. This means that people receiving Ozempic were less likely to experience at least one of the following:

  • Loss of 50% or more of their kidney function

  • Kidney failure

  • Dialysis

  • Kidney transplant

  • Death from kidney disease

  • Death from cardiovascular disease

People with CKD have a higher risk of heart attack, stroke, and cardiovascular death. During the trial, people receiving Ozempic also had a lower risk of having at least one of these events, and a lower risk of death from any cause.

The results of the FLOW trial were so significant that it ended early to avoid disadvantaging participants who were receiving a placebo instead of Ozempic.

Potential kidney benefits for other groups

Other research suggests that semaglutide may also benefit kidney health in other groups of people, and not just in people with diabetes. Here’s what the findings have shown:

  • People with Type 2 diabetes and heart disease: Participants taking Ozempic had lower rates of new or worsening kidney disease.

  • People with Type 2 diabetes and a high BMI: Those taking Wegovy had improvements in albuminuria (protein leaking), a key marker of damaged kidneys. 

  • People with heart disease and high BMI without diabetes: In the Wegovy group, people had a lower rate of kidney disease-related events, a slower decline in kidney function, and improvements in albuminuria.

Limitations

The clinical trial data on semaglutide’s kidney benefits are promising. But high-risk populations that could significantly benefit from treatment have been underrepresented in the research.

For example, most participants in these semaglutide trials were white. There was limited representation from other racial and ethnic groups disproportionately affected by Type 2 diabetes and CKD, such as Black populations. Plus, many of these trials had mostly male participants.

Future studies should aim for greater diversity to confirm whether Ozempic’s benefits apply to all populations.

How does Ozempic protect the kidneys?

Ozempic protects the kidneys by lowering blood sugar levels and excess body weight — both of which can contribute to kidney disease. It works in a few different ways to have these effects:

  • Telling the pancreas to release insulin after you eat

  • Slowing the movement of food out of the stomach

  • Reducing glucose production in the liver

  • Working on areas of the brain that regulate your appetite and fullness

Researchers are still studying the exact mechanisms behind semaglutide’s kidney benefits. But they think that semaglutide’s kidney benefits may go beyond these effects alone. 

Other possible contributing factors may include:

  • Lowering inflammation in the kidneys and blood vessels

  • Improving blood flow to the kidneys

  • Reducing the buildup of scar tissue in the kidneys

  • Lowering blood pressure

  • Removing excess sodium through the urine

Who could benefit from Ozempic for kidney health?

With this FDA approval, Ozempic is now an important option for improving outcomes among adults with both Type 2 diabetes and CKD, likely alongside other kidney-protective medications, such as ACE inhibitors, ARBs, and SGLT2 inhibitors.

Even for people without CKD, Ozempic can help manage key risk factors for kidney health, such as high blood sugar and excess body weight. If you’re living with Type 2 diabetes, talk to your healthcare team about whether Ozempic could be a good addition to your treatment plan.

Can Ozempic also be harmful to the kidneys?

Ozempic isn’t known to be directly harmful to the kidneys. In fact, it has proven kidney-related benefits for certain people. But some side effects, such as vomiting and diarrhea, can lead to dehydration. Severe dehydration can temporarily worsen kidney function, especially for people who already have (or are at high risk for) kidney problems.

Staying hydrated and contacting your prescriber if you experience persistent vomiting or diarrhea can help reduce this risk.

The bottom line

Ozempic (semaglutide) is a once-weekly injection that’s approved to treat Type 2 diabetes, lower the risk of serious cardiovascular problems, and protect from worsening chronic kidney disease in certain groups.

Some studies suggest that semaglutide’s kidney benefits may even extend to certain people without diabetes.

For now, if you’re living with Type 2 diabetes and CKD, talk to your healthcare team to see if Ozempic could benefit you.

why trust our exports reliability shield

Why trust our experts?

Alyssa Billingsley, PharmD, is the director of pharmacy content for GoodRx. She has over a decade of experience as a pharmacist and has worked in clinical, academic, and administrative roles.
Sophie Vergnaud, MD, is the Senior Medical Director for GoodRx Health. A pulmonologist and hospitalist, she practiced and taught clinical medicine at hospitals in London for a decade before entering a career in health education and technology.

References

GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.

Was this page helpful?

Latest articles